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Glioblastoma (GBM) is the most common primary brain 
tumour with dismal prognosis. Tumours exhibit inherent 
resistance to radiation and chemotherapy which has been 
attributed to a subpopulation of cancer cells termed ‘GBM 
stem-like cells’ (GSC) characterised by multipotentiality and 
potent tumorigenic capacity. The use of established cancer 
cell lines in simplified two-dimensional (2D) in vitro cultures 
might explain the observed discrepancy between pre-clinical 
and clinical responses to cytotoxic treatments. We developed 
a customised, 3D GSC culture system using a polystyrene 
scaffold (Alvetex®) that recapitulates key histological 
features of GBM including high cellularity and sparse 
extracellular matrix (ECM) and compared it to conventional 
2D GSC cultures. 2D and 3D cultures of three different 
primary GSC lines exhibited similar radiation sensitivities as 
measured by clonogenic survival. Previous studies have 
demonstrated radiopotentiating efficacy of the epidermal 
growth factor receptor (EGFR) inhibitor erlotinib against GBM 
cell lines in 2D cultures; however it failed in GBM clinical 
trials. Thus we evaluated the radiation modifying effects of 
erlotinib on 2D and 3D GSC cultures. Erlotinib enhanced 
radiosensitivity of 2D GSC cultures but had no effect on 
radiation responses of 3D GSC or in neurosphere formation 
assays, where cells grow in 3D conditions devoid of a scaffold 
or extrinsic ECM. We next examined VEGF inhibition, since 
anti-VEGF therapy in combination with standard radio-
chemotherapy increases progression-free survival of GBM 
patients. VEGF deprivation was associated with significant 
radiosensitisation of 3D GSC cultures but had no effect on 2D 
GSC. Erlotinib treatment of VEGF-deprived 3D cultures 
increased radiation resistance of 3D cells to the same extent 
as VEGF addition, indicating epistasis. EGFR has been shown 
to regulate repair of radiation-induced double-strand breaks 
by activating the non-homologous end-joining (NHEJ) repair 
protein DNA-PKcs. A correlation between radiosensitivity, 
increased gH2AX foci and phospho-DNA-PK nuclear foci after 
radiation treatment was observed. In contrast, increased 
numbers of foci of the homologous recombination (HR) repair 
protein Rad51 were observed in radioresistant populations. 
Our results show that in the 3D model, VEGF signalling is 
required for optimal NHEJ activation with fast kinetics. This 
effect allows access to HR repair proteins at the remaining 
unrepaired DSBs at later time points, facilitating their repair 
and conferring radiation protection. Detailed analysis of the 
signalling pathways involved in the radiation resistance 
conferred by VEGF and EGFR signalling in the 3D and 2D 
models respectively demonstrated a radioprotective role of 
the downstream signaling molecule Akt. Specific inhibition of 
Akt using the small molecule inhibitor MK-2206 increased 
radiation sensitivity to the same extent as VEGF deprivation 
in 3D cells or erlotinib treatment in 2D cells, and no 
additivity was observed when these agents were combined. 
Our results for erlotinib treatment and VEGF deprivation in 
the 3D model recapitulate data from clinical trials, and 
suggest novel therapeutic targets for GBM. The 3D-specific 
effects of this panel of molecularly targeted agents strongly 
support the clinical relevance of this 3D model and its 
potential value in preclinical studies. 
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Tumour-specific immunity occurs in cancer patients but has 
insufficient potential to control or eliminate the tumour. 
Strengthening this response through immunotherapy may lead 
to a durable, systemic response that may also control 
(development of)metastases. 
Radiotherapy - a standard treatment for cancer - acts 
through induction of DNA damage in cancer cells. Although 
this treatment was thought to e immuno suppressive for a 
long time, recent data show that radiotherapy can support 
tumour-specific immunity. In fact, there is accumulating 
evidence that immune stimulation is an integral part of this 
therapy. 
Using preclinical cancer models we showed that the efficacy 
of radiotherapy crucially depends on CD8+ T cells and 
dendritic cells. Radiotherapy induces activation of tumour-
associated dendritic cells and accumulation of CD8+ T cells 
with protective effect or function within the tumour (1). 
These results prompted us to investigate whether similar 
changes occur in cancer patients and we compared the 
immune signature in paired biopsies that were obtained from 
sarcoma patients before and after radiotherapy. Most 
patients showed a significant upregulation of molecules and 
cell types associated with protective immunity and a 
concomitant downregulation of such characteristic for 
immune regulation/suppression. Importantly, those patients 
with the strongest changes towards protective immunity 
survived longer after radiotherapy (2, 3). 
Because it is largely unknown how radiotherapy supports 
tumour-specific immunity, we performed a semi-unbiased 
transcript analysis to identify pathways that change 
significantly upon radiotherapy. We found that radiotherapy 
induces transient and local activation of the classical and 
alternative pathway of complement in murine and human 
tumours, which results in local production of the 
anaphylatoxins C3a and C5a. Complement activation and 
subsequent production of anaphylatoxins happens 
downstream of radiotherapy-induced necrosis. The local 
production of C3a andC5a is crucial to clinical efficacy of 
radiotherapy and concomitant stimulation of tumour-specific 
immunity (4). 
Radiotherapy influences a plethora of pathways, which we 
are currently identifying, because we think that selectively 
promoting or inhibiting particular pathways in the context of 
radiotherapy may further promote tumour-specific immunity 
and increase the therapeutic efficacy.Because chronic 
inflammation is immunosuppressive whereas acute inflation 
supports immunity, we are comparing chronic radiotherapy 
(low-dose given in multiple fractions during weeks) with 
radiotherapy that includes radiation holidays (limited 
fractions of high-dose given with substantial breaks) with 
respect to efficacy and immune stimulation.  
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Summary: Whole Brain Radiotherapy (WBRT) may be 
administered with either prophylactic or palliative intent. I 
will discuss both these approaches and how they fit into our 
management of metastatic brain disease in the 21st century. 
 
Background: The use of Whole Brain Radiotherapy (WBRT) 
emerged as standard management for patients with brain 
metastases during the latter half of the 20th century (1,2,3). 
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This practice is based on reported experience from single 
institutions. 
In the first decade of the 21st century, local control using 
stereotactic radiotherapy or surgical resection of individual 
brain metastases has emerged as a clinically beneficial 
modality for highly selected patients. Whole brain 
radiotherapy is increasingly seen as a treatment provided in 
addition to this local control, or is held in reserve for salvage 
management should new or recurrent brain metastases 
develop at a later date – without RCT evidence supporting 
this approach (4,5,6).  
The majority of patients with brain metastases, however, are 
not suitable for stereotactic or surgical approaches and WBRT 
continues to be seen as the standard of care for this group, 
particularly if they are perceived to have a durable prognosis 
(5). Until the MRC QUARTZ trial was undertaken in non-small 
cell lung cancer (NSCLC) (Mulvenna et al 2016-in press), there 
were no sufficiently powered randomised controlled trials 
specifically addressing the utility of WBRT compared to 
supportive care (7).  
Although prophylactic cranial irradiation has enhanced 
overall survival and reduced incidence of brain metastases 
for patients with the exquisitely radiosensitive small cell 
variant of lung cancer, trials addressing this issue in NSCLC 
and Breast cancer have failed to accrue. This lack of high 
quality evidence added to the fear of neurocognitive decline 
remains a potential barrier to applying this technique to 
other solid tumours with a propensity for metastasising to the 
brain. 
 
Questions to address: 
Can we apply prognostic indices reliably to all solid tumour 
types? 
Do we really know which patients will benefit from WBRT, 
whether used as a sole palliative modality or as an adjunct to 
local (stereotactic or surgical) modalities?  
If so, how can we best use Image Guided radiotherapy to 
minimise long term neurocognitive impact? 
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Brain metastases (BM) develop in up to 30% of patients with 
cancer. There is marked heterogeneity in outcomes for 
patients with BM, and these outcomes vary not only by 
diagnosis, but also by diagnosis-specific prognostic factors; 
we should not treat all patients with brain metastases the 
same way, treatment should be individualized. 
Phase III randomized trials have shown that upfront whole 
brain radiotherapy (WBRT) may decrease brain recurrence 
both in terms of better local and improved distant brain 
tumour control rate, and that neurological death rate may be 
reduced in patients treated with WBRT + stereotactic 
radiosurgery (SRS), but no survival benefit is reached. The 
EORTC 22952-26001 study (Kocher M et al) shows that 
adjuvant WBRT fails to improve the duration of functional 
independence. 
The use of SRS in the treatment of multiple BM has increased 
dramatically during the past decade to avoid the 
neurocognitive dysfunction induced by WBRT. 
One of the biggest (1194 patients) multi-institutional 
prospective observational studies (JLGK0901, Yamamoto M et 
al and Watanabe S et al) including patients with multiple BM 
(even more than 10) have shown that SRS without WBRT in 
patients with five to ten BM is non-inferior to that in patients 
with two to four BM in terms of median OS (10,8 months for 
both groups), 1-year local recurrence (6,5% and 7%), with a 
very low incidence of side effects (less than 3%). They also 
concluded that carefully selected patients with 10 or more 
BM are not unfavourable candidates for SRS alone, having 
these patients a median survival time and neurological death-
free survival times comparables to the group with 9-10 BM; 
their results suggest also that even among patients 80 years 
and older, those with modified-RPA Class I+IIa or IIb disease 
are considered to be favourable candidates for more 
aggressive treatment of BM. 
SRS has been an option for limited (1-3) metastatic brain 
lesions, and nowadays the updated guidelines (for example, 
the NCCN panel) have recently added SRS as a primary 
treatment option for multiple (>3) metastatic lesions. 
The exclusive SRS approach for patients with multiple BM is 
mostly curative for each treated lesion, it can be repeated 
several times (the limits in terms of median cumulative dose 
to the normal brain must be explored), and WBRT remains an 
option as salvage treatment. 
Exclusive SRS with frequent magnetic resonance imaging-
based follow-ups (every 2-3 months) in order to salvage 
recurrent BM before symptomatic manifestations, should be 
routinely offered to selected patients as a treatment option 
to consider (Lester SC et al). Initial treatment with a 
combination of SRS and close clinical monitoring should be 
recommended as the preferred treatment strategy to better 
preserve learning and memory in good prognosis patients 
with newly diagnosed BM (Chang EL et al). 
The Lausanne University Hospital (CHUV) has created a brain 
metastases clinic to provide medical and radiation oncology, 
neurosurgical, and supportive services to this complex 
patient population. During the first 18 months, 250 cases 
were discussed, 55% of patients had more than one brain 
metastases, and focal treatments were proposed in 69% of 
treated cases (for 50% of them radiosurgery or fractionated 
stereotactic radiotherapy, FSRT). WBRT was proposed to only 
16% of patients (some of them as salvage therapy after 
sequential treatments with SRS). 
Higher BM burden (in terms of size and volume) and higher 
integral SRS dose to the brain are the main predictive factors 
for late toxicity after SRS. The cumulative neurocognitive 
effect of numerous SRS sessions remains unknown. In order to 
reduce the cumulative median dose to the brain, the SRS 
technique must be carefully chosen. 
At CHUV, we have performed a dosimetric comparison study 
in cases with multiple brain metastases (up to 10), comparing 
a radiosurgical planning (same dose and isodose prescription) 
with Gamma Knife (GK), CyberKnife (CK), VMAT and Helical 
Tomotherapy (HT). Gradient index was better with GK and CK 
(3.4 and 4.1, compared to 17.8 and 19), as well as PTV 
coverage (100% with GK and CK, compared to 97% with VMAT 
and 90% with HT); brain Dmean was lower with GK (3 Gy) and 
CK (2.66 Gy), compared to VMAT (6.4 Gy) and HT (6.72 Gy). 
SRS alone should be considered a routine treatment option in 
patients with multiple BM due to favourable neurocognitive 
outcomes, less risk of late side effects, without adversely 
affecting the patients performance status. 
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